[HTML][HTML] Cytokine disturbances in systemic lupus erythematosus
N Jacob, W Stohl - Arthritis research & therapy, 2011 - Springer
N Jacob, W Stohl
Arthritis research & therapy, 2011•SpringerThe pathogenesis of systemic lupus erythematosus (SLE) is complex, and the resulting
disease manifestations are heterogeneous. Cytokine dysregulation is pervasive, and their
protein and gene expression profiles may serve as markers of disease activity and severity.
Importantly, biologic agents that target specific cytokines may represent novel therapies for
SLE. Four cytokines (IL-6, TNFα, IFNα, and BLyS) are being evaluated as therapeutic targets
in SLE. The present review will examine the roles of each of these cytokines in murine and …
disease manifestations are heterogeneous. Cytokine dysregulation is pervasive, and their
protein and gene expression profiles may serve as markers of disease activity and severity.
Importantly, biologic agents that target specific cytokines may represent novel therapies for
SLE. Four cytokines (IL-6, TNFα, IFNα, and BLyS) are being evaluated as therapeutic targets
in SLE. The present review will examine the roles of each of these cytokines in murine and …
Abstract
The pathogenesis of systemic lupus erythematosus (SLE) is complex, and the resulting disease manifestations are heterogeneous. Cytokine dysregulation is pervasive, and their protein and gene expression profiles may serve as markers of disease activity and severity. Importantly, biologic agents that target specific cytokines may represent novel therapies for SLE. Four cytokines (IL-6, TNFα, IFNα, and BLyS) are being evaluated as therapeutic targets in SLE. The present review will examine the roles of each of these cytokines in murine and human SLE, and will summarize results from clinical trials of agents that target these cytokines.
Springer